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Following the original article\'s publication \[[@CR1]\] the authors asked for the correction of Fig. [2](#Fig1){ref-type="fig"}, since the names of the disease genes \[*GCH1* and *PCBD1*\] in the figure published did not match the listed diseases \[AR-GTPCHD and PCDD\]. The correct Fig. [2](#Fig1){ref-type="fig"} is shown below: Fig. 2Diagnostic flowchart for differential diagnosis of BH~4~Ds with and without HPA. ^1^Consider genetic HPA workup depending on availability and financial resources. The gene panel should include the *QDPR, GCH1, PTS PCBD1, SPR* genes as well as *DNAJC12.* For *GCH1*, consider MLPA if Sanger sequencing is negative. ^2^The analysis in urine is more sensitive than in DBS and pathological patterns suggestive for PCDD and SRD can only be detected in urine but not in DBS. ^3^Primapterin measurement in urine is only elevated in PCDD. ^4^Aminoacids in CSF are not required for diagnosis of BH~4~Ds. ^5^CSF analysis should always include standard measurements (cell count, proteins, glucose and lactate). ^6^Recommendation against measurements of HVA, 5-HIAA, 5-MTHF, and pterins in CSF in the case of PCDD. (\*) A diagnostic L-Dopa trial should be limited to children with symptoms suggestive of dopa-responsive dystonia or to situations where biochemical and genetic diagnostic tools are not available. If the diagnostic L-Dopa trial is positive but the results of CSF biochemical and/or molecular genetic testing are not compatible with AD-GTPCHD or SRD, further aetiologies for dopa responsive dystonia should be considered (e.g. juvenile parkinsonism (PARK2gene)). (\*\*) Can be considered if available. See text for more detailed information. Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; 5-MTHF, 5-methyltetrahydrofolate; AA: amino acids; AD−/AR- GTPCHD: guanosine triphosphate cyclohydrolase I deficiency; BH~4~, tetrahydrobiopterin; Bio: biopterin; CSF: cerebrospinal fluid; DBS: dry blood spot; DHPR: q-dihydropteridine reductase; DHPRD, dihydropteridine reductase deficiency; HVA, homovanillic acid; MRI, magnetic resonance imaging; N: normal; NBS: newborn screening; Neo: neopterin; NR: not reported; PAH: phenylalanine hydroxylase; Phe: phenylalanine; PKU: phenylketonuria; Prim: primapterin; PTPSD, 6-pyruvoyltetrahydropterin synthase deficiency; SRD: sepiapterin reductase deficiency; Tyr: tyrosine; u: urine; (+) = positive effect; (−) = no or no clear effect

In the context of the manuscript correction and in order to match the text content, the words \"apart from DHPRD\" should be removed from the second row and second column of Table [4](#Tab1){ref-type="table"}, as shown below: Table 4Recommended drugs and doses for BH~4~ disordersDisorderStarting doseDosesTarget doseMaximum doseManagement suggestionComment**First line treatmentsPhe-reduced diet**All BH~4~D with HPATitrate Phe restriction according to Phe levels in DBS or plasmaFollow PKU national treatment recommendationsUse either Phe reduced diet or Sapropterin dihydrochloride to control Phe levels**Sapropterin dihydrochloride**All BH~4~D with HPA2-5 mg/kg BW/dayDivided in 1--3 doses/ day5--10 mg/kg BW/day20 mg/kg BW/dayTitrate dose according to Phe levels in DBS or plasmaFollow PKU national treatment recommendationsUse either Phe reduced diet or Sapropterin dihydrochloride to control Phe levels**L-Dopa/DC inhibitor (carbidopa/benserazide) 4:1**All BH~4~D apart from PCDD0.5 mg--1 mg/kg BW/dayDose recommendation relates to L-Dopa component!Divided in 2--6 doses/ dayAD-GTPCHD:3--7 mg/kg BW/dayAll other BH~4~D:10 mg/kg BW/day or maximally tolerated dosageDose recommendation relates to L-Dopa component!Depending on clinical symptoms.Some patients need more than 10 mg/kg BW/day for resolving clinical symptomsIncrease 0.5--1 mg/kg BW/day per weekFollow BW adaption until the BW of 40 kg.After 40 kg adjust depending on clinical symptomsConsider analysis of CSF HVA for dose adjustmentIn young infants at least as many dosages as meals would be ideal (usually 5--6 /day)**5-Hydroxytryptophan (5-HTP)**All BH~4~D apart from AD-GTPCHD and PCDD1--2 mg/kg BW/dayDivided in 3--6 doses/dayPublished target dose recommendations are highly variable5-HTP doses are usually lower than L-Dopa dosesTitrate slowly (1--2 mg/kg BW/day per week)depending on clinical picture and side effectsConsider analysis of CSF 5HIAA for dose finding5-HTP should follow L-Dopa/DCI treatment initiationAlways in combination with a peripheral decarboxylase inhibitor (for example by simultaneous application with L-Dopa/DC inhibitor)**Folinic acid**In DHPRD and all BH~4~D with low 5-MTHF in CSFDivided in 1--2 doses/day10--20 mg/dayNo titration neededConsider analysis of CSF 5MTHF for dose finding**Second line treatmentsPramipexole**^**a**^(Dopamine agonist)All BH~4~D apart from PCDD3.5--7 μg/kg/BW/day (base)5--10 μg/kgBW/day (salt)Note: Distinction in salt and base content!(see product insert)Divided in 3 equal doses/dayTitrate to clinical Symptoms75 μg/kg BW/day(3.3 mg/d base / 4 mg/d salt)Increaseevery 7 days by5 μg/kg BW/d**Bromocriptine**^**a**^(Dopamine agonist)All BH~4~D apart from PCDD0.1 mg/kg BW/dayDivided in 2--3 doses/dayTitrate to clinical Symptoms0.5 mg/kg/d(or 30 mg/d)Increaseevery 7 days by0.1 mg/kg BW/d**Rotigotine**^**a**^(transdermal dopamine agonist)All BH~4~D apart from PCDD2 mg/dayTitrate to clinical Symptoms8 mg/dayIncrease weekly by1 mgChildren \> 12 yearsExchange patch every 24 h**Selegiline**^**a**^(MAO B inhibitor)All BH~4~D apart from PCDD0.1 mg/kg BW/dayDivided in 2 (−3) doses/dayTitrate to clinical Symptoms0.3 mg/kg/d(or 10 mg/d)Increase every 2 weeks by0.1 mg/kg BW/dCan cause sleep disturbances -- morning and afternoon or lunchtime dosage is possibleATTENTION: orally disintegrating preparation needs much less dosage because the first-pass effect of the liver is avoided**Third line treatmentsTrihexyphenidyl**^**a**^(Anticholinergic drugs)All BH~4~D apart from PCDD\< 15 kg: start 0.5--1 mg/day\> 15 kg: start 2 mg/day\< 15 kg: in 1 dose\> 15 kg:in 2 dosesEffective dose highly variable(6--60 mg)Titrate to clinical SymptomsMaximum dose:\< 15 kg BW30 mg/day\> 15 kg BW60 mg/dIncrease every 7 daysby 1--2 mg/d in2--4 doses/dConsider side effects: like dry mouth, dryeyes, blurred vision (mydriasis),urine retention, constipation.**Entacapone**^**a**^(COMT inhibitor)All BH~4~D apart from PCDD200 mg(adult)Up to 2.000 mgIn many countries licensed only for adults.Comedication with L-Dopa/DC inhibitorConsider reduction of concomitant L-Dopa supplementation (10--30%)**Sertaline**^**a**^(SSRI)All BH~4~D apart from PCDD6--12 years: 25 mg/dayin 1 dose\> 12 years: 50 mg/day in 1 dose6--12 years:in 1 dose\> 12 years:in 1 doseChildren 50 mg/day50 mg/day\< 12 years200 mg/day\> 12 years6--12 years: increase after 7 days to 50 mg/dayin 1 dose\> 12 years 50 mg/day in 1 doseDon't stop treatment suddenlyNote: Elevated risk of serotonin syndrome(SS) or malignant neurolepticsyndrome (MNS) when used with drugs impacting serotonergic pathway (e.g. 5-HTP, MAO inhibitors)**Melatonin**^**a**^All BH~4~D apart from PCDD0.01--0.03 mg/kg/day5--8 mg/daySlow release preparation for sleep-maintenance insomnia available in some countriesPlease note: The doses given are in a range typically used and have been published. In individual patients, some adjustment may be necessary depending on symptom response and side effects^a^The evaluated literature did not provide BH~4~D specific treatment dose recommendations for this drug. The listed doses, therefore, indicate treatment recommendations from Summary of Product Characteristics (SmPC) or neurotransmitter related publications (e.g. \[119\])*Abbreviations*: *5-HIAA* 5-hydroxyindoleacetic acid, *5-HTP* 5-hydroxytryptophan, *5-MTHF* 5- methyltetrahydrofolate, *HVA* Homovanillic acid, *AD-GTPCHD* Autosomal-dominant guanosine triphosphate cyclohydrolase I deficiency, *BH*~*4*~*D* Tetrahydrobiopterin deficiency, *BW* Body weight, *COMT* Catechol-O-methyl transferase, *CSF* Cerebrospinal fluid, *DBS* Dry blood spot, *DC* Decarboxylase, *DCI* Decarboxylase inhibitor, *DHPRD* Dihydropteridine reductase deficiency, *L-Dopa* L-3,4-dihydroxyphenylalanine, *MAO B* Monoamine oxidase B, *PCDD* Pterin-4-alpha-carbinolamine dehydratase deficiency, *Phe* Phenylalanine, *PKU* Phenylketonuria, *SSRI* Selective serotonin reuptake inhibitor
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